FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases.

FIBREX Medical has identified several anti-inflammatory peptides as lead compounds. The most advanced product of FIBREX Medical – FX06 – prevents reperfusion injury after myocardial infarction and aims at markets with more than 5,000,000 potential patients per year in the Western World.